Cargando…
NRD.E1, an innovative non‐opioid therapy for painful diabetic peripheral neuropathy—A randomized proof of concept study
BACKGROUND: Painful diabetic peripheral neuropathy (PDPN) affects up to 26% of patients with diabetes mellitus, with major impacts on their general health and well‐being. Most available drugs fail to deliver acceptable pain reduction in the majority of patients and are often poorly tolerated. NRD.E1...
Autores principales: | Tiecke, Eva, Rainisio, Maurizio, Eisenberg, Elon, Wainstein, Julio, Kaplan, Eli, Silverberg, Michal, Hochman, Liat, Mangialaio, Sara |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9540529/ https://www.ncbi.nlm.nih.gov/pubmed/35671086 http://dx.doi.org/10.1002/ejp.1989 |
Ejemplares similares
-
First‐in‐Human Single‐Ascending‐Dose, Multiple‐Dose, and Food Interaction Studies of NRD.E1, an Innovative Nonopioid Therapy for Painful Diabetic Peripheral Neuropathy
por: Tiecke, Eva, et al.
Publicado: (2022) -
Human nuclear RNAi-defective 2 (NRDE2) is an essential RNA splicing factor
por: Jiao, Alan L., et al.
Publicado: (2019) -
NRDE2 negatively regulates exosome functions by inhibiting MTR4 recruitment and exosome interaction
por: Wang, Jianshu, et al.
Publicado: (2019) -
Structural basis of Nrd1–Nab3 heterodimerization
por: Chaves-Arquero, Belén, et al.
Publicado: (2022) -
Structure and semi-sequence-specific RNA binding of Nrd1
por: Bacikova, Veronika, et al.
Publicado: (2014)